-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Nitronazine in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nitronazine in Type 2 Diabetes report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nitronazine in Type 2 Diabetes Drug Details: Nitronazine is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nitronazine in Amyotrophic Lateral Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nitronazine in Amyotrophic Lateral Sclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nitronazine in Amyotrophic Lateral Sclerosis Drug Details: Nitronazine is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nitronazine in Acute Ischemic Stroke
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nitronazine in Acute Ischemic Stroke report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nitronazine in Acute Ischemic Stroke Drug Details: Nitronazine is under development for...
-
Product Insights
Myocardial Ischemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Myocardial Ischemia - Drugs In Development, 2023’, provides an overview of the Myocardial Ischemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myocardial Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Alport Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Alport Syndrome - Drugs In Development, 2023’, provides an overview of the Alport Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alport Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Vascular Dementias – Drugs In Development, 2023
Global Markets Direct’s, ‘Vascular Dementias - Drugs In Development, 2023’, provides an overview of the Vascular Dementias pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vascular Dementias, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Pulmonary Arterial Hypertension – Drugs In Development, 2023
Global Markets Direct’s, ‘Pulmonary Arterial Hypertension - Drugs In Development, 2023’, provides an overview of the Pulmonary Arterial Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Pulmonary Hypertension – Drugs In Development, 2023
Global Markets Direct’s, ‘Pulmonary Hypertension - Drugs In Development, 2023’, provides an overview of the Pulmonary Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pulmonary Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...